UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)

Br J Haematol. 2009 Oct;147(1):22-42. doi: 10.1111/j.1365-2141.2009.07807.x. Epub 2009 Aug 10.

Authors

Jenny Bird¹, Judith Behrens, Jan Westin, Ingemar Turesson, Mark Drayson, Robert Beetham, Shirley D'Sa, Richard Soutar, Anders Waage, Nina Gulbrandsen, Henrik Gregersen, Eric Low; Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study Group

Affiliation

¹ Avon Haematology Unit, Bristol Haematology and Oncology Centre, Bristol, UK. bcsh@b-s-h.org.uk

PMID: 19673884
DOI: 10.1111/j.1365-2141.2009.07807.x

No abstract available

Publication types

Practice Guideline
Research Support, Non-U.S. Gov't

MeSH terms

Algorithms
Biomarkers / blood
Cell Transformation, Neoplastic
Diagnosis, Differential
Disease Progression
Humans
Immunoglobulins / blood*
Long-Term Care / methods
Lymphoproliferative Disorders / diagnosis
Monoclonal Gammopathy of Undetermined Significance / diagnosis*
Monoclonal Gammopathy of Undetermined Significance / epidemiology
Multiple Myeloma / diagnosis
Prognosis
Waldenstrom Macroglobulinemia / diagnosis

Substances

Biomarkers
Immunoglobulins
M-proteins (Myeloma)